FFB’s own Dr. Steve Rose, chief scientific officer, reviews our commitment to funding and exploring CRISPR/Cas9 gene editing for inherited retinal disease in the video below.
FFB currently funds CRISPR/Cas9 projects at four institutions:
Johns Hopkins University (retinitis pigmentosa caused by the P23H mutation in RHO) Columbia University (RP caused by the D190N mutation in RHO) Massachusetts Eye and Ear Infirmary (RP caused by a mutation in RP1) UCLA (Usher syndrome 1B caused by a mutation in MYO7A)
Want to learn more about the benefits of CRISPR/Cas9? Check out: A Cut-and-Paste Approach to Fixing Retinal-Disease Genes